[MiR-217 Targeting PI3K/Akt Pathway Enhances Sensitivity of Adriamycin to Acute Myeloid Leukemia]

To investigate the effects of miR-217 on proliferation and adriamycin sensitivity of acute myeloid leukemia (AML) cells.

The mimic NC and miR-217 mimic vectors were constructed and transfected into HL-60 cells, and transfection efficiency was detected by qPCR. The cells were treated with different concentrations of adriamycin for 24 h and 48 h. CCK-8 assay was used to detect the chemical sensitivity of adriamycin and screen the optimal concentration and time of adriamycin treatment. Cells were divided into control group, mimic NC group, miR-217 mimic group, adriamycin group and miR-217 mimic+adriamycin group. Apoptosis was detected by flow cytometry, and the expressions of miR-217, PI3K and Akt3 were detected by qPCR. Western blot was used to detect the expression of PI3K/Akt pathway proteins PI3K, Akt3 and apoptosis proteins Bcl-2, Bax, and double luciferase was used to verify the relationship between miR-217 and Akt3.

MiR-217 mimic could enhance the sensitivity of HL-60 cells to adriamycin. The optimal concentration and treatment time of adriamycin were 160 ng/ml and 48 h, respectively. Compared with control group, apoptosis rate, miR-217 and Bax protein levels were significantly increased in miR-217 mimic and adriamycin groups (P < 0.01), while Bcl-2 protein, PI3K, Akt3 mRNA and protein levels were significantly decreased (P < 0.01). Compared with adriamycin group, apoptosis rate, miR-217 and Bax protein levels were significantly increased in miR-217 mimic+adriamycin group (P < 0.01), while Bcl-2 protein, PI3K, Akt3 mRNA and protein levels were significantly decreased (P < 0.01). Dual luciferase assay showed that there was a targeted regulatory relationship between miR-217 and Akt3.

MiR-217 regulates the PI3K/Akt pathway targeting Akt3, inhibits cell proliferation, promotes cell apoptosis and enhances the sensitivity of adriamycin to AML cells.